The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics

The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics




The Department of Veterans Affairs CIO Says no to Breast Cancer Genomics being added to The Veterans Affairs New VISTA S.O.A stratergy.

Scott Cragg, Special Assistant to the CIO, U.S. Department of Veterans Affairs and his Team.
John Teeter, Deputy Chief Information Officer, Department of Health and Human Services. CAPT Michael Weiner, Chief Medical Officer for the Defense Health Information Management System (DHIMS) Ed Meagher, Director, Strategic Healthcare Initiatives, SRA International; former Deputy Chief Information Officer, Dept. of Veterans Affairs (moderator) made their comments at the
AFFIRM The Association for Federal Information Resources Management ( http://affirm.org/ )May Monthly Luncheon on Health IT

The Department of Veterans affirs has a new System Called Veterans Health Information Systems and Technology Architecture (VISTA) said that they are not Including Genomics as a part of their VISTA system.

Genomics is the study of complex sets of genes, how they are expressed in cells (what their level of activity is), and the role they play in biology. Another way to think about it is as a small network of genes and how they work together to influence the a Veterans Breast CancerTumor's biology and behavior.

VISTA is built on a client-server architecture, which ties together workstations and personal computers with graphical user interfaces at Veterans Health Administration (VHA) facilities, as well as software developed by local medical facility staff. VISTA also includes the links that allow commercial off-the-shelf software and products to be used with existing and future
technologies. The Decision Support System (DSS) and other national databases that might be derived from locally generated data lie outside the scope of VISTA.

Hybrid Medical Analytics Our focus is on Genomic Trials. Genomics Science looks at groups of genes and how active they are. This activity can influence how a cancer is likely to grow and respond to treatment. Unlike a genetic test, that provide information about a person's inherited genetic make-up. Instead,

Hybrid Medical Analytics looks at 21 genes in a patient's breast tumor trials to understand how these genes interact and influence the tumor's behavior.


Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems


Hybrid Medical Electronic e-Clinicals and early stage trials that allows
us unique insight into the most prevalent challenges at this phase of
testing. We have strategically built an infrastructure, methodology
and facility that meet those needs.

82% Increase in Transgenic R&D for Breast Cancer that is Carcinogenesis caused by Li-Fraumeni Syndrome

82% Increase in Transgenic R&D for Breast Cancer that is carcinogenesis caused by Li-Fraumeni syndrome. Hybrid Medical focused on:

Family history and other risk factors for breast Cancer.
Models for predicting breast cancer risk.
Major genes associated with breast cancer
Screening and risk modification for hereditary breast cancer
Psychosocial issues associated with hereditary breast cancer

Among women, breast cancer is the most commonly diagnosed cancer after nonmelanoma skin cancer.

The syndromes most strongly associated with Breast cancers are BRCA1 or BRCA2 mutation syndromes. Breast cancer is also a common feature of Li-Fraumeni syndrome due to P53 mutations.

Breast Cancer research for a cure has a new friend. P53 or mP53. Mutant in transgenic mice has shown promise in the cure for Breast Cancer. Hybrid Medical e-Clinical generated transgenic
mice carrying mutant p53. We cloned the m53 cDNA from a radiation-induced mouse tumor.

The tumors was treated via a potent atelocollagen suppression of the tumors growth. The Result that mp53 activity caused tumors that can be suppressed by subsequent silencing of the mp53.

This is great news because if you get a Genomics Test and discover that you have Brac1 or Brac2one of the major causes of Breast Cancer, the mP53 Mutant can be suppressed and extend Life

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Pluripotent Stem Cells & Neurotransmitter is a Breast Cancer Game changer for pain.

Pluripotent Stem Cells & Neurotransmitter is a Breast Cancer Game changer for pain.

Hybrid Medical Analytics research focuses on identifying the cause of chronic pain an ion pump dysfunction in the nervous system that disrupts neurotransmitter signaling.

Breast Cancer pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, Breast Cancer pain can be managed effectively through relatively simple means in up to 90% of Breast Cancer Patients.

Identifying the etiology of pain is important to its management.

Neurotransmitters is showing Promise. billions of neurons in the mammalian brain communicate with each other with liberating chemical messengers that are detected by receptors on adjacent cells.

These chemical messengers, or neurotransmitters, can be ions, amino acids, amino acid derivatives, or large polypeptides.

Gene targeting in embryonic stem cells to generate dopamine-deficient .
Gene targeting in embryonic Pluripotent Stem Cell can be the अन्स्वेर




Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Diagnosed with Breast Cancer Analytics eNotebook CIO Reports a 47% Increase in Ex Vivo Activation

Diagnosed with Breast Cancer Hybrid Medical Analytics eNotebook CIO Reports a 47% Increase in Ex Vivo Activation of Peripheral Stem cell. Hematopoietic or blood stem cell transplants are also
called bone marrow transplants.

Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or
radiation therapy. There are three types of transplants:

• In autologous transplants,is where Breast Cancer patients receive their own stem cells.

• In syngeneic transplants,is where patients receive stem cells from a identical twin.

• In allogeneic transplants, patients receive stem cells from their brother, sister, or parent.

• A person who is not related to the patient (an unrelated donor) also may be used.

Hybrid Medical Analytics is a leader in unrelated donor Stem Cells
The primary use for BMT and PBSCT is to minimize any damage to blood stem cells from Breast Cancer treatment, these stem cells from the bone marrow are removed and preserved before patients receive chemotherapy.
The stem cells are then re-infused into the patient after chemotherapy where they migrate to the bone marrow and begin producing new blood cells.

After the stem cell transplantationentering the bloodstream, the stem cells travel to the bone marrow, where they begin to produce new white blood cells, red blood cells, and platelets in a process known as “engraftment.” Engraftment usually occurs within about 2 to 4 weeks after transplantation.
Doctors monitor it by checking blood counts on a frequent basis. Complete recovery of immune function takes much longer, however—up to several months for autologous transplant recipients
and 1 to 2 years for patients receiving allogeneic or syngeneic transplants. Doctors evaluate the results of various blood tests to confirm that new blood cells are being produced and that
the cancer has not returned. Bone marrow aspiration (the removal of a small sample of bone marrow through a needle for examination under a microscope) can also help doctors determine
how well the new marrow is working.

If you have a relative that can not find a Stem Cell match contact Hybrid Medical Analytics Inc


Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Breast Cancer happens when changes occur in Your DNA

Breast Cancer happens when changes occur in your DNA Your Genes Proteins are not made correctly. A protein may be missing, overproduced, shortened, or assembled with alterations.

We know that Breast Cancer arises when a cell undergoes several molecular changes. These changes can take place over many years, and only when the cell has accumulated a critical number of these changes will become a "cancerous" cells.

At Hybrid Medical Analytics our focus is Genomic Science. Genomic Science studies how each organism has its own unique genome. A human genome has 22 pairs of chromosomes and a pair of sex chromosomes.

The human genome has 25,000 genes spread across all 23 pairs of human chromosomes. When a gene "switches on," it eventually makes a protein and thus Breast Cancer

Genomic converts the gene codes an intermediary molecule called mRNA, this transfer a gene's information from DNA to mRNA which allows us to distinguish mRNA from DNA. Using Hybrid Medical informatics scientist can recommend the proper therapy for treating Breast cancer and extend the life of a Breast Cancer patient



Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Hybrid Medical It is a New Day in Breast Cancer Treatment

Hybrid Medical Analytics it is a New Day in Breast Cancer.

The question is which targeted Breast Cancer Therapy is best for a individual Patients. Is Genomics the Anwser ?

Hybrid Medical Analytics CIO Reports when Researchers sequence the genomes of 14 triple-negative breast cancer patients with tumors that have progressed despite multiple therapies Breast Cancer patients have a new way to extend life.

The triple-negative tumors make up nearly 20% of breast cancers and do not respond to standard targeted therapies.

In Hybrid Medical Partners Clinical Trials Scientist study both Tumors and Healthy Tissue Sequenced. Then Scientists collaborate on the development using informatics from Hybrid Medical Analytics software that is used with whole genome sequencing. What Scientist in clinical trials Attempt to show how one new drug can be safe and effective for hundreds of people.

Hybrid Medical eLab Notebooks Genomics uses sequencing data from one individual to evaluate which anticancer drugs could be most effective based on normal and tumor genetic makeup

Our Clinical Trial Partners are showing a 80% effective rate using the Genomics Science approach

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

15 % of Black Women to 7 % of White Women are diagnosed with Breast Cancer. Can Genomics be the Tool to low the rate in which black women are dia

15 percent of Black Women to 7 percent of White Women are diagnosed with Breast Cancer. Can Genomics be the tool to low the rate in which black women are diagnosed with Breast Cancer and extend their lives.

We know that there are 194,280 Americans will be diagnosed with breast cancer this year and 40,610 will die from the disease. 15 percent Black to 7 percent White.

Some guidelines recommend that Cancer stem cells is the fuel that grow Breast Cancer tumor's. Others guidelines recommend that bone mineral density is the fuel that grows tumors.
Chemotherapies do not work against these cells, which is why cancer recurs and spreads. Hybrid Medical Analytics believe that eliminating the cancer stem cells is key to controlling cancer.

21 percent of black women and 15 percent of white women do not receive the minimum expected treatment. Black Women have shorter survival and higher mortality observed for black women
compared to white women.The correlation of lower social class and the lack of Health Care equals less screening, and later stage diagnosis.

Can Genomics be the answer for Black women ? Genomics Science looks at groups of genes and how active they are. This activity can influence how a cancer is likely to grow and respond to treatment.
Hybrid Medical Analytics Genomics Science looks at 21 genes in a patient’s breast cancer tumor in trials to understand how these genes interact and influence the tumor’s behavior.

Genomics is personalized treatment that will reduce the rate of cancer for Black Women.

Tamoxifen and Raloxifene works the same for Balck and White Women, but to many Black Women say the treatment can be toxic. Black Women state that too much toxicity leads to not taking the treatment.

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems